Call Options

6 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$4.18 - $7.35 $7,941 - $13,965
-1,900 Reduced 79.17%
500 $2,000
Q1 2024

May 15, 2024

BUY
$4.47 - $6.47 $10,728 - $15,528
2,400 New
2,400 $15,000
Q3 2023

Nov 14, 2023

SELL
$4.23 - $7.53 $10,998 - $19,578
-2,600 Reduced 18.18%
11,700 $51,000
Q2 2023

Aug 14, 2023

BUY
$7.15 - $9.78 $41,470 - $56,723
5,800 Added 68.24%
14,300 $103,000
Q1 2023

May 15, 2023

SELL
$6.62 - $9.57 $1,324 - $1,914
-200 Reduced 2.3%
8,500 $64,000
Q4 2022

Feb 14, 2023

BUY
$8.78 - $12.47 $76,386 - $108,489
8,700 New
8,700 $83,000

Others Institutions Holding PRPH

About ProPhase Labs, Inc.


  • Ticker PRPH
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 16,024,400
  • Market Cap $9.77M
  • Description
  • ProPhase Labs, Inc. engages in the research, development, manufacture, distribution, marketing, and sale of over the counter (OTC) consumer healthcare products and dietary supplements in the United States. The company operates in two segments, Diagnostic Services and Consumer Products. It offers a range of OTC dietary supplements, including Lege...
More about PRPH
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.